Candel Therapeutics, Inc. CADL Deferred income
Deferred income at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s deferred income?
- Candel Therapeutics, Inc. (CADL) reported deferred income of $67K in Q1 2026.
- What is the long-term trend for Candel Therapeutics, Inc.'s deferred income?
- Over 3 years (2020 to 2025), Candel Therapeutics, Inc.'s deferred income has grown at a -10.7% compound annual growth rate (CAGR), from $125K to $89K.